Solventum has struck a deal to acquire Acera Surgical, a bioscience company specialising in synthetic, regenerative wound-care materials, for US$ 725 million plus up to $125 million in milestone payments a move that significantly bolsters its advanced wound-care portfolio.

Glimpse:

With this acquisition, Solventum enters the high-growth synthetic tissue matrices market, leveraging Acera’s proprietary electrospinning platform and Restrata® products to address complex wounds. The deal is expected to close in H1 2026, be slightly dilutive in 2026, and become EPS-accretive from 2027.

Solventum has agreed to acquire Acera Surgical for US$ 725 million in cash, along with an additional $125 million contingent on future milestones, according to its latest announcement. Acera is a leader in advanced synthetic materials for wound repair, leveraging its proprietary electrospinning technology to produce the Restrata® line designed for difficult-to-heal, complex wounds in acute care.

By bringing Acera into its fold, Solventum is expanding into the synthetic tissue matrices category, a rapidly growing segment in the U.S. acute-care wound market, pegged at nearly $900 million. The acquisition is highly strategic: Solventum plans to leverage its global footprint, specialized wound-care sales team, and expertise in negative-pressure wound therapy to accelerate the adoption of Acera’s products. projected to generate around US$ 90 million in sales in 2025. Solventum will fund the deal using its cash reserves no new debt is being taken on. The company expects closing in the first half of 2026, after which integration will begin. In terms of earnings per share, the deal is projected to be slightly dilutive in 2026 but accretive beginning in 2027.

“Regenerative wound care is among the most promising frontiers in medicine with Acera’s electrospun technology and our go-to-market muscle, we’re unlocking real hope for patients with complex wounds.”